Trial Outcomes & Findings for Pain Control Using Neuromodulation in Patients Undergoing Definitive Chemoradiotherapy for Head and Neck Cancer (NCT NCT02366611)
NCT ID: NCT02366611
Last Updated: 2021-01-22
Results Overview
A Visual Analog Scale (VAS) will be used to assess patient-reported odynophagia at weekly Radiation Oncology on-treatment visits (OTVs). The VAS is a traditional pain assessment tool that has been used and validated widely in both clinical and research settings, including studies of oral mucositis pain. This scale ranges from 0-100, in which 0 means no odynophagia, and 100 means highest level of odynophagia ever.
Recruitment status
COMPLETED
Study phase
NA
Target enrollment
11 participants
Primary outcome timeframe
Pre-treatment (baseline), throughout treatment (once a week for 7 weeks), 1 week and 1 month follow-ups (post-treatment)
Results posted on
2021-01-22
Participant Flow
Participant milestones
| Measure |
Transcranial Direct Current Stimulation (tDCS)
tDCS is a method of non-invasive brain stimulation that is based on the application of a weak direct current to the head that flows between two relatively large electrodes-anode and cathode. tDCS offers a unique analgesic modality of central pain neuromodulation by altering the activity of key sensory and motor cortical structures. Participants in this arm will undergo 20 tDCS sessions, tDCS in clinic and remotely supervised tDCS, and 2mA of transcranial direct current stimulation will be applied for 20 minutes.
Transcranial Direct Current Stimulation (tDCS): tDCS is a non-invasive brain neuromodulatory method that involves sending a weak electrical current to the brain. 2mA of tDCS will be applied for 20 minutes at each session and participants will undergo a total of 20 sessions over a 7-week period.
|
Chemoradiotherapy Standard of Care
The control group will consist of patients receiving the Standard of care and no neuromodulation.
|
|---|---|---|
|
Overall Study
STARTED
|
10
|
1
|
|
Overall Study
COMPLETED
|
8
|
1
|
|
Overall Study
NOT COMPLETED
|
2
|
0
|
Reasons for withdrawal
Withdrawal data not reported
Baseline Characteristics
Race and Ethnicity were not collected from any participant.
Baseline characteristics by cohort
| Measure |
Transcranial Direct Current Stimulation (tDCS)
n=10 Participants
tDCS is a method of non-invasive brain stimulation that is based on the application of a weak direct current to the head that flows between two relatively large electrodes-anode and cathode. tDCS offers a unique analgesic modality of central pain neuromodulation by altering the activity of key sensory and motor cortical structures. Participants in this arm will undergo 20 tDCS sessions, tDCS in clinic and remotely supervised tDCS, and 2mA of transcranial direct current stimulation will be applied for 20 minutes.
Transcranial Direct Current Stimulation (tDCS): tDCS is a non-invasive brain neuromodulatory method that involves sending a weak electrical current to the brain. 2mA of tDCS will be applied for 20 minutes at each session and participants will undergo a total of 20 sessions over a 7-week period.
|
Chemoradiotherapy Standard of Care
n=1 Participants
The control group will consist of patients receiving the Standard of care and no neuromodulation.
|
Total
n=11 Participants
Total of all reporting groups
|
|---|---|---|---|
|
Age, Continuous
|
60.3 years
STANDARD_DEVIATION 8.1 • n=10 Participants
|
58 years
STANDARD_DEVIATION NA • n=1 Participants
|
60.1 years
STANDARD_DEVIATION 7.7 • n=11 Participants
|
|
Sex: Female, Male
Female
|
2 Participants
n=10 Participants
|
0 Participants
n=1 Participants
|
2 Participants
n=11 Participants
|
|
Sex: Female, Male
Male
|
8 Participants
n=10 Participants
|
1 Participants
n=1 Participants
|
9 Participants
n=11 Participants
|
|
Race and Ethnicity Not Collected
|
—
|
—
|
0 Participants
Race and Ethnicity were not collected from any participant.
|
PRIMARY outcome
Timeframe: Pre-treatment (baseline), throughout treatment (once a week for 7 weeks), 1 week and 1 month follow-ups (post-treatment)A Visual Analog Scale (VAS) will be used to assess patient-reported odynophagia at weekly Radiation Oncology on-treatment visits (OTVs). The VAS is a traditional pain assessment tool that has been used and validated widely in both clinical and research settings, including studies of oral mucositis pain. This scale ranges from 0-100, in which 0 means no odynophagia, and 100 means highest level of odynophagia ever.
Outcome measures
| Measure |
Transcranial Direct Current Stimulation (tDCS)
n=7 Participants
tDCS is a method of non-invasive brain stimulation that is based on the application of a weak direct current to the head that flows between two relatively large electrodes-anode and cathode. tDCS offers a unique analgesic modality of central pain neuromodulation by altering the activity of key sensory and motor cortical structures. Participants in this arm will undergo 20 tDCS sessions, tDCS in clinic and remotely supervised tDCS, and 2mA of transcranial direct current stimulation will be applied for 20 minutes.
Transcranial Direct Current Stimulation (tDCS): tDCS is a non-invasive brain neuromodulatory method that involves sending a weak electrical current to the brain. 2mA of tDCS will be applied for 20 minutes at each session and participants will undergo a total of 20 sessions over a 7-week period.
|
Chemoradiotherapy Standard of Care
n=1 Participants
The control group will consist of patients receiving the Standard of care and no neuromodulation.
|
|---|---|---|
|
Visual Analog Scale (VAS)
Pre Study
|
16 score on a scale
Standard Deviation 22
|
2 score on a scale
|
|
Visual Analog Scale (VAS)
Week1
|
11 score on a scale
Standard Deviation 14
|
0 score on a scale
|
|
Visual Analog Scale (VAS)
Week2
|
11 score on a scale
Standard Deviation 14
|
0 score on a scale
|
|
Visual Analog Scale (VAS)
Week3
|
25 score on a scale
Standard Deviation 19
|
0 score on a scale
|
|
Visual Analog Scale (VAS)
Week4
|
34 score on a scale
Standard Deviation 31
|
0 score on a scale
|
|
Visual Analog Scale (VAS)
Week5
|
32 score on a scale
Standard Deviation 28
|
0 score on a scale
|
|
Visual Analog Scale (VAS)
Week6
|
40 score on a scale
Standard Deviation 19
|
0 score on a scale
|
|
Visual Analog Scale (VAS)
Week7
|
36 score on a scale
Standard Deviation 18
|
0 score on a scale
|
|
Visual Analog Scale (VAS)
Follow Up Week 1
|
29 score on a scale
Standard Deviation 19
|
0 score on a scale
|
|
Visual Analog Scale (VAS)
Follow Up Month 1
|
31 score on a scale
Standard Deviation 15
|
0 score on a scale
|
PRIMARY outcome
Timeframe: Week1/Week7EEG data power spectrum analysis. Week1 and Week 7 difference. Note: the control participant's data was not reported due to limited number of participant in the control group. The report was divided into five frequency bands: * Delta = 0-4 Hz * Theta = 4-7 Hz * Alpha = 8-15 Hz * Beta= 16-31 Hz * Gamma 32-50 Hz The data was recorded at P3, Fz, Cz, F3, Fp1, Fp2 points in the international 10-20 system. The analysis was done using EEGLab V 14.1.1.
Outcome measures
| Measure |
Transcranial Direct Current Stimulation (tDCS)
n=4 Participants
tDCS is a method of non-invasive brain stimulation that is based on the application of a weak direct current to the head that flows between two relatively large electrodes-anode and cathode. tDCS offers a unique analgesic modality of central pain neuromodulation by altering the activity of key sensory and motor cortical structures. Participants in this arm will undergo 20 tDCS sessions, tDCS in clinic and remotely supervised tDCS, and 2mA of transcranial direct current stimulation will be applied for 20 minutes.
Transcranial Direct Current Stimulation (tDCS): tDCS is a non-invasive brain neuromodulatory method that involves sending a weak electrical current to the brain. 2mA of tDCS will be applied for 20 minutes at each session and participants will undergo a total of 20 sessions over a 7-week period.
|
Chemoradiotherapy Standard of Care
n=1 Participants
The control group will consist of patients receiving the Standard of care and no neuromodulation.
|
|---|---|---|
|
EEG Power Spectrum Week1/Week7
Gamma_Week1_Fp2
|
108.7 Power(10*log10(muV))^2
Standard Deviation 0.2
|
52.6 Power(10*log10(muV))^2
|
|
EEG Power Spectrum Week1/Week7
Delta_Week7_Fp2
|
129.1 Power(10*log10(muV))^2
Standard Deviation 3.1
|
127.6 Power(10*log10(muV))^2
|
|
EEG Power Spectrum Week1/Week7
Theta_Week7_Fp2
|
123.0 Power(10*log10(muV))^2
Standard Deviation 1.6
|
91.7 Power(10*log10(muV))^2
|
|
EEG Power Spectrum Week1/Week7
Alpha_Week7_Fp2
|
119.0 Power(10*log10(muV))^2
Standard Deviation 1.4
|
79 Power(10*log10(muV))^2
|
|
EEG Power Spectrum Week1/Week7
Beta_Week7_Fp2
|
111.4 Power(10*log10(muV))^2
Standard Deviation 2.1
|
67.9 Power(10*log10(muV))^2
|
|
EEG Power Spectrum Week1/Week7
Gamma_Week7_Fp2
|
106.6 Power(10*log10(muV))^2
Standard Deviation 1.1
|
56.9 Power(10*log10(muV))^2
|
|
EEG Power Spectrum Week1/Week7
Delta_Week1_P3
|
118.9 Power(10*log10(muV))^2
Standard Deviation 2.4
|
111 Power(10*log10(muV))^2
|
|
EEG Power Spectrum Week1/Week7
Theta_Week1_P3
|
115.3 Power(10*log10(muV))^2
Standard Deviation 0.3
|
86.9 Power(10*log10(muV))^2
|
|
EEG Power Spectrum Week1/Week7
Alpha_Week1_P3
|
115.4 Power(10*log10(muV))^2
Standard Deviation 0.5
|
74 Power(10*log10(muV))^2
|
|
EEG Power Spectrum Week1/Week7
Beta_Week1_P3
|
114.2 Power(10*log10(muV))^2
Standard Deviation 0.2
|
61.6 Power(10*log10(muV))^2
|
|
EEG Power Spectrum Week1/Week7
Gamma_Week1_P3
|
115 Power(10*log10(muV))^2
Standard Deviation 0.3
|
50.1 Power(10*log10(muV))^2
|
|
EEG Power Spectrum Week1/Week7
Delta_Week7_P3
|
129.5 Power(10*log10(muV))^2
Standard Deviation 3.3
|
127.6 Power(10*log10(muV))^2
|
|
EEG Power Spectrum Week1/Week7
Theta_Week7_P3
|
123.5 Power(10*log10(muV))^2
Standard Deviation 1.5
|
91.7 Power(10*log10(muV))^2
|
|
EEG Power Spectrum Week1/Week7
Alpha_Week7_P3
|
118.3 Power(10*log10(muV))^2
Standard Deviation 1.8
|
78.9 Power(10*log10(muV))^2
|
|
EEG Power Spectrum Week1/Week7
Beta_Week7_P3
|
112.0 Power(10*log10(muV))^2
Standard Deviation 2.0
|
66.9 Power(10*log10(muV))^2
|
|
EEG Power Spectrum Week1/Week7
Gamma_Week7_P3
|
107.4 Power(10*log10(muV))^2
Standard Deviation 1.0
|
55.4 Power(10*log10(muV))^2
|
|
EEG Power Spectrum Week1/Week7
Delta_Week1_Fz
|
118.6 Power(10*log10(muV))^2
Standard Deviation 2.8
|
126.4 Power(10*log10(muV))^2
|
|
EEG Power Spectrum Week1/Week7
Theta_Week1_Fz
|
114.7 Power(10*log10(muV))^2
Standard Deviation 0.2
|
90.5 Power(10*log10(muV))^2
|
|
EEG Power Spectrum Week1/Week7
Alpha_Week1_Fz
|
113.3 Power(10*log10(muV))^2
Standard Deviation 1.4
|
77.5 Power(10*log10(muV))^2
|
|
EEG Power Spectrum Week1/Week7
Beta_Week1_Fz
|
110.8 Power(10*log10(muV))^2
Standard Deviation 0.2
|
64.5 Power(10*log10(muV))^2
|
|
EEG Power Spectrum Week1/Week7
Gamma_Week1_Fz
|
111.7 Power(10*log10(muV))^2
Standard Deviation 0.4
|
51.3 Power(10*log10(muV))^2
|
|
EEG Power Spectrum Week1/Week7
Delta_Week7_Fz
|
146.7 Power(10*log10(muV))^2
Standard Deviation 2.9
|
127.1 Power(10*log10(muV))^2
|
|
EEG Power Spectrum Week1/Week7
Theta_Week7_Fz
|
141.9 Power(10*log10(muV))^2
Standard Deviation 1.6
|
91.2 Power(10*log10(muV))^2
|
|
EEG Power Spectrum Week1/Week7
Alpha_Week7_Fz
|
137.1 Power(10*log10(muV))^2
Standard Deviation 1.7
|
78.6 Power(10*log10(muV))^2
|
|
EEG Power Spectrum Week1/Week7
Beta_Week7_Fz
|
129.3 Power(10*log10(muV))^2
Standard Deviation 2.1
|
68.1 Power(10*log10(muV))^2
|
|
EEG Power Spectrum Week1/Week7
Gamma_Week7_Fz
|
124.0 Power(10*log10(muV))^2
Standard Deviation 1.2
|
57.6 Power(10*log10(muV))^2
|
|
EEG Power Spectrum Week1/Week7
Delta_Week1_Cz
|
117.9 Power(10*log10(muV))^2
Standard Deviation 2.5
|
125.5 Power(10*log10(muV))^2
|
|
EEG Power Spectrum Week1/Week7
Theta_Week1_Cz
|
114.3 Power(10*log10(muV))^2
Standard Deviation 0.2
|
89.6 Power(10*log10(muV))^2
|
|
EEG Power Spectrum Week1/Week7
Alpha_Week1_Cz
|
113.3 Power(10*log10(muV))^2
Standard Deviation 1.3
|
76.5 Power(10*log10(muV))^2
|
|
EEG Power Spectrum Week1/Week7
Beta_Week1_Cz
|
110.7 Power(10*log10(muV))^2
Standard Deviation 0.3
|
63.7 Power(10*log10(muV))^2
|
|
EEG Power Spectrum Week1/Week7
Gamma_Week1_Cz
|
111.4 Power(10*log10(muV))^2
Standard Deviation 0.3
|
51 Power(10*log10(muV))^2
|
|
EEG Power Spectrum Week1/Week7
Delta_Week7_Cz
|
141.7 Power(10*log10(muV))^2
Standard Deviation 3.1
|
126.5 Power(10*log10(muV))^2
|
|
EEG Power Spectrum Week1/Week7
Theta_Week7_Cz
|
136.5 Power(10*log10(muV))^2
Standard Deviation 1.6
|
90.6 Power(10*log10(muV))^2
|
|
EEG Power Spectrum Week1/Week7
Alpha_Week7_Cz
|
132.3 Power(10*log10(muV))^2
Standard Deviation 1.5
|
77.9 Power(10*log10(muV))^2
|
|
EEG Power Spectrum Week1/Week7
Beta_Week7_Cz
|
123.8 Power(10*log10(muV))^2
Standard Deviation 2.5
|
67.1 Power(10*log10(muV))^2
|
|
EEG Power Spectrum Week1/Week7
Gamma_Week7_Cz
|
118.3 Power(10*log10(muV))^2
Standard Deviation 1.1
|
56.4 Power(10*log10(muV))^2
|
|
EEG Power Spectrum Week1/Week7
Delta_Week1_F3
|
118.6 Power(10*log10(muV))^2
Standard Deviation 3.2
|
125.9 Power(10*log10(muV))^2
|
|
EEG Power Spectrum Week1/Week7
Theta_Week1_F3
|
114.1 Power(10*log10(muV))^2
Standard Deviation 0.3
|
90 Power(10*log10(muV))^2
|
|
EEG Power Spectrum Week1/Week7
Alpha_Week1_F3
|
113.1 Power(10*log10(muV))^2
Standard Deviation 1.1
|
77 Power(10*log10(muV))^2
|
|
EEG Power Spectrum Week1/Week7
Beta_Week1_F3
|
110.7 Power(10*log10(muV))^2
Standard Deviation 0.4
|
64 Power(10*log10(muV))^2
|
|
EEG Power Spectrum Week1/Week7
Gamma_Week1_F3
|
111.1 Power(10*log10(muV))^2
Standard Deviation 0.3
|
49.8 Power(10*log10(muV))^2
|
|
EEG Power Spectrum Week1/Week7
Delta_Week7_F3
|
140.3 Power(10*log10(muV))^2
Standard Deviation 3.7
|
129.5 Power(10*log10(muV))^2
|
|
EEG Power Spectrum Week1/Week7
Theta_Week7_F3
|
133.9 Power(10*log10(muV))^2
Standard Deviation 1.2
|
94.1 Power(10*log10(muV))^2
|
|
EEG Power Spectrum Week1/Week7
Alpha_Week7_F3
|
127.7 Power(10*log10(muV))^2
Standard Deviation 2.1
|
81.1 Power(10*log10(muV))^2
|
|
EEG Power Spectrum Week1/Week7
Beta_Week7_F3
|
121.3 Power(10*log10(muV))^2
Standard Deviation 2.1
|
69.4 Power(10*log10(muV))^2
|
|
EEG Power Spectrum Week1/Week7
Gamma_Week7_F3
|
116.1 Power(10*log10(muV))^2
Standard Deviation 1.2
|
57.2 Power(10*log10(muV))^2
|
|
EEG Power Spectrum Week1/Week7
Delta_Week1_Fp1
|
119.0 Power(10*log10(muV))^2
Standard Deviation 4.1
|
130 Power(10*log10(muV))^2
|
|
EEG Power Spectrum Week1/Week7
Theta_Week1_Fp1
|
113.0 Power(10*log10(muV))^2
Standard Deviation 0.5
|
94.1 Power(10*log10(muV))^2
|
|
EEG Power Spectrum Week1/Week7
Alpha_Week1_Fp1
|
110.9 Power(10*log10(muV))^2
Standard Deviation 1.5
|
81.1 Power(10*log10(muV))^2
|
|
EEG Power Spectrum Week1/Week7
Beta_Week1_Fp1
|
109.0 Power(10*log10(muV))^2
Standard Deviation 0.2
|
68.3 Power(10*log10(muV))^2
|
|
EEG Power Spectrum Week1/Week7
Gamma_Week1_Fp1
|
109.0 Power(10*log10(muV))^2
Standard Deviation 0.2
|
53.1 Power(10*log10(muV))^2
|
|
EEG Power Spectrum Week1/Week7
Delta_Week7_Fp1
|
132.3 Power(10*log10(muV))^2
Standard Deviation 2.9
|
129.5 Power(10*log10(muV))^2
|
|
EEG Power Spectrum Week1/Week7
Theta_Week7_Fp1
|
127.3 Power(10*log10(muV))^2
Standard Deviation 1.6
|
93.2 Power(10*log10(muV))^2
|
|
EEG Power Spectrum Week1/Week7
Alpha_Week7_Fp1
|
122.6 Power(10*log10(muV))^2
Standard Deviation 1.5
|
80.3 Power(10*log10(muV))^2
|
|
EEG Power Spectrum Week1/Week7
Beta_Week7_Fp1
|
114.5 Power(10*log10(muV))^2
Standard Deviation 2.2
|
68.3 Power(10*log10(muV))^2
|
|
EEG Power Spectrum Week1/Week7
Gamma_Week7_Fp1
|
109.3 Power(10*log10(muV))^2
Standard Deviation 1.1
|
56 Power(10*log10(muV))^2
|
|
EEG Power Spectrum Week1/Week7
Delta_Week1_Fp2
|
120.4 Power(10*log10(muV))^2
Standard Deviation 3.8
|
128.8 Power(10*log10(muV))^2
|
|
EEG Power Spectrum Week1/Week7
Theta_Week1_Fp2
|
115.0 Power(10*log10(muV))^2
Standard Deviation 0.5
|
92.9 Power(10*log10(muV))^2
|
|
EEG Power Spectrum Week1/Week7
Alpha_Week1_Fp2
|
112.4 Power(10*log10(muV))^2
Standard Deviation 1.5
|
80 Power(10*log10(muV))^2
|
|
EEG Power Spectrum Week1/Week7
Beta_Week1_Fp2
|
108.8 Power(10*log10(muV))^2
Standard Deviation 0.7
|
67.2 Power(10*log10(muV))^2
|
PRIMARY outcome
Timeframe: Pre/Post-tDCS SessionPopulation: Because this piece of result compared EEG data pre- and post- tDCS stimulation, however the control (regular CRT) arm was not stimulated, thus the data were not collected and presented below.
EEG data power spectrum analysis. Pre/Post-tDCS session. The report was divided into five frequency bands: * Delta = 0-4 Hz * Theta = 4-7 Hz * Alpha = 8-15 Hz * Beta= 16-31 Hz * Gamma 32-50 Hz The data was recorded at P3, Fz, Cz, F3, Fp1, Fp2 points in the international 10-20 system. Note: the control participant's data was not reported due to limited number of participant in the control group.
Outcome measures
| Measure |
Transcranial Direct Current Stimulation (tDCS)
n=5 Participants
tDCS is a method of non-invasive brain stimulation that is based on the application of a weak direct current to the head that flows between two relatively large electrodes-anode and cathode. tDCS offers a unique analgesic modality of central pain neuromodulation by altering the activity of key sensory and motor cortical structures. Participants in this arm will undergo 20 tDCS sessions, tDCS in clinic and remotely supervised tDCS, and 2mA of transcranial direct current stimulation will be applied for 20 minutes.
Transcranial Direct Current Stimulation (tDCS): tDCS is a non-invasive brain neuromodulatory method that involves sending a weak electrical current to the brain. 2mA of tDCS will be applied for 20 minutes at each session and participants will undergo a total of 20 sessions over a 7-week period.
|
Chemoradiotherapy Standard of Care
The control group will consist of patients receiving the Standard of care and no neuromodulation.
|
|---|---|---|
|
EEG Spectrum Pre-Post tDCS Session
Theta_Pre_F3
|
111.4 Power(10*log10(muV))^2
Standard Deviation 0.4
|
—
|
|
EEG Spectrum Pre-Post tDCS Session
Delta_Pre_F3
|
115.7 Power(10*log10(muV))^2
Standard Deviation 2.8
|
—
|
|
EEG Spectrum Pre-Post tDCS Session
Delta_Pre_P3
|
114.8 Power(10*log10(muV))^2
Standard Deviation 2.3
|
—
|
|
EEG Spectrum Pre-Post tDCS Session
Theta_Pre_P3
|
111.0 Power(10*log10(muV))^2
Standard Deviation 0.2
|
—
|
|
EEG Spectrum Pre-Post tDCS Session
Alpha_Pre_P3
|
109.8 Power(10*log10(muV))^2
Standard Deviation 1.1
|
—
|
|
EEG Spectrum Pre-Post tDCS Session
Beta_Pre_P3
|
105.9 Power(10*log10(muV))^2
Standard Deviation 1.0
|
—
|
|
EEG Spectrum Pre-Post tDCS Session
Gamma_Pre_P3
|
104.5 Power(10*log10(muV))^2
Standard Deviation 0.1
|
—
|
|
EEG Spectrum Pre-Post tDCS Session
Delta_Post_P3
|
115.6 Power(10*log10(muV))^2
Standard Deviation 2.6
|
—
|
|
EEG Spectrum Pre-Post tDCS Session
Theta_Post_P3
|
112.2 Power(10*log10(muV))^2
Standard Deviation 0.4
|
—
|
|
EEG Spectrum Pre-Post tDCS Session
Alpha_Post_P3
|
111.9 Power(10*log10(muV))^2
Standard Deviation 1.2
|
—
|
|
EEG Spectrum Pre-Post tDCS Session
Beta_Post_P3
|
109 Power(10*log10(muV))^2
Standard Deviation 0.4
|
—
|
|
EEG Spectrum Pre-Post tDCS Session
Gamma_Post_P3
|
108.8 Power(10*log10(muV))^2
Standard Deviation 0.2
|
—
|
|
EEG Spectrum Pre-Post tDCS Session
Delta_Pre_Fz
|
115.4 Power(10*log10(muV))^2
Standard Deviation 2.4
|
—
|
|
EEG Spectrum Pre-Post tDCS Session
Theta_Pre_Fz
|
111.4 Power(10*log10(muV))^2
Standard Deviation 0.3
|
—
|
|
EEG Spectrum Pre-Post tDCS Session
Alpha_Pre_Fz
|
109.1 Power(10*log10(muV))^2
Standard Deviation 1.5
|
—
|
|
EEG Spectrum Pre-Post tDCS Session
Beta_Pre_Fz
|
104.7 Power(10*log10(muV))^2
Standard Deviation 1.1
|
—
|
|
EEG Spectrum Pre-Post tDCS Session
Gamma_Pre_Fz
|
103.1 Power(10*log10(muV))^2
Standard Deviation 0.1
|
—
|
|
EEG Spectrum Pre-Post tDCS Session
Delta_Post_Fz
|
115.3 Power(10*log10(muV))^2
Standard Deviation 2.6
|
—
|
|
EEG Spectrum Pre-Post tDCS Session
Theta_Post_Fz
|
111.7 Power(10*log10(muV))^2
Standard Deviation 0.3
|
—
|
|
EEG Spectrum Pre-Post tDCS Session
Alpha_Post_Fz
|
110 Power(10*log10(muV))^2
Standard Deviation 1.6
|
—
|
|
EEG Spectrum Pre-Post tDCS Session
Beta_Post_Fz
|
106.7 Power(10*log10(muV))^2
Standard Deviation 0.5
|
—
|
|
EEG Spectrum Pre-Post tDCS Session
Gamma_Post_Fz
|
106.3 Power(10*log10(muV))^2
Standard Deviation 0.2
|
—
|
|
EEG Spectrum Pre-Post tDCS Session
Delta_Pre_Cz
|
115.9 Power(10*log10(muV))^2
Standard Deviation 2.2
|
—
|
|
EEG Spectrum Pre-Post tDCS Session
Theta_Pre_Cz
|
112.1 Power(10*log10(muV))^2
Standard Deviation 0.3
|
—
|
|
EEG Spectrum Pre-Post tDCS Session
Alpha_Pre_Cz
|
110 Power(10*log10(muV))^2
Standard Deviation 1.3
|
—
|
|
EEG Spectrum Pre-Post tDCS Session
Beta_Pre_Cz
|
105.8 Power(10*log10(muV))^2
Standard Deviation 1.1
|
—
|
|
EEG Spectrum Pre-Post tDCS Session
Gamma_Pre_Cz
|
103.9 Power(10*log10(muV))^2
Standard Deviation 0.1
|
—
|
|
EEG Spectrum Pre-Post tDCS Session
Delta_Post_Cz
|
116.4 Power(10*log10(muV))^2
Standard Deviation 2.5
|
—
|
|
EEG Spectrum Pre-Post tDCS Session
Theta_Post_Cz
|
112.9 Power(10*log10(muV))^2
Standard Deviation 0.2
|
—
|
|
EEG Spectrum Pre-Post tDCS Session
Alpha_Post_Cz
|
111.3 Power(10*log10(muV))^2
Standard Deviation 1.4
|
—
|
|
EEG Spectrum Pre-Post tDCS Session
Beta_Post_Cz
|
107.4 Power(10*log10(muV))^2
Standard Deviation 0.8
|
—
|
|
EEG Spectrum Pre-Post tDCS Session
Gamma_Post_Cz
|
106.5 Power(10*log10(muV))^2
Standard Deviation 0.2
|
—
|
|
EEG Spectrum Pre-Post tDCS Session
Alpha_Pre_F3
|
109.3 Power(10*log10(muV))^2
Standard Deviation 1.2
|
—
|
|
EEG Spectrum Pre-Post tDCS Session
Beta_Pre_F3
|
105.6 Power(10*log10(muV))^2
Standard Deviation 0.8
|
—
|
|
EEG Spectrum Pre-Post tDCS Session
Gamma_Pre_F3
|
104.3 Power(10*log10(muV))^2
Standard Deviation 0.1
|
—
|
|
EEG Spectrum Pre-Post tDCS Session
Delta_Post_F3
|
115.9 Power(10*log10(muV))^2
Standard Deviation 2.8
|
—
|
|
EEG Spectrum Pre-Post tDCS Session
Theta_Post_F3
|
112 Power(10*log10(muV))^2
Standard Deviation 0.2
|
—
|
|
EEG Spectrum Pre-Post tDCS Session
Alpha_Post_F3
|
110.4 Power(10*log10(muV))^2
Standard Deviation 1.4
|
—
|
|
EEG Spectrum Pre-Post tDCS Session
Beta_Post_F3
|
107.8 Power(10*log10(muV))^2
Standard Deviation 0.3
|
—
|
|
EEG Spectrum Pre-Post tDCS Session
Gamma_Post_F3
|
107.6 Power(10*log10(muV))^2
Standard Deviation 0.2
|
—
|
|
EEG Spectrum Pre-Post tDCS Session
Delta_Pre_Fp1
|
115.5 Power(10*log10(muV))^2
Standard Deviation 3.0
|
—
|
|
EEG Spectrum Pre-Post tDCS Session
Theta_Pre_Fp1
|
110.8 Power(10*log10(muV))^2
Standard Deviation 0.4
|
—
|
|
EEG Spectrum Pre-Post tDCS Session
Alpha_Pre_Fp1
|
108.4 Power(10*log10(muV))^2
Standard Deviation 1.4
|
—
|
|
EEG Spectrum Pre-Post tDCS Session
Beta_Pre_Fp1
|
104.6 Power(10*log10(muV))^2
Standard Deviation 0.9
|
—
|
|
EEG Spectrum Pre-Post tDCS Session
Gamma_Pre_Fp1
|
103 Power(10*log10(muV))^2
Standard Deviation 0.1
|
—
|
|
EEG Spectrum Pre-Post tDCS Session
Delta_Post_Fp1
|
114.8 Power(10*log10(muV))^2
Standard Deviation 2.8
|
—
|
|
EEG Spectrum Pre-Post tDCS Session
Theta_Post_Fp1
|
110.9 Power(10*log10(muV))^2
Standard Deviation 0.3
|
—
|
|
EEG Spectrum Pre-Post tDCS Session
Alpha_Post_Fp1
|
109.0 Power(10*log10(muV))^2
Standard Deviation 1.6
|
—
|
|
EEG Spectrum Pre-Post tDCS Session
Beta_Post_Fp1
|
105.7 Power(10*log10(muV))^2
Standard Deviation 0.5
|
—
|
|
EEG Spectrum Pre-Post tDCS Session
Gamma_Post_Fp1
|
105.1 Power(10*log10(muV))^2
Standard Deviation 0.1
|
—
|
|
EEG Spectrum Pre-Post tDCS Session
Delta_Pre_Fp2
|
114.9 Power(10*log10(muV))^2
Standard Deviation 2.7
|
—
|
|
EEG Spectrum Pre-Post tDCS Session
Theta_Pre_Fp2
|
110.4 Power(10*log10(muV))^2
Standard Deviation 0.4
|
—
|
|
EEG Spectrum Pre-Post tDCS Session
Alpha_Pre_Fp2
|
108 Power(10*log10(muV))^2
Standard Deviation 1.5
|
—
|
|
EEG Spectrum Pre-Post tDCS Session
Beta_Pre_Fp2
|
104 Power(10*log10(muV))^2
Standard Deviation 0.9
|
—
|
|
EEG Spectrum Pre-Post tDCS Session
Gamma_Pre_Fp2
|
102.4 Power(10*log10(muV))^2
Standard Deviation 0.1
|
—
|
|
EEG Spectrum Pre-Post tDCS Session
Delta_Post_Fp2
|
114.8 Power(10*log10(muV))^2
Standard Deviation 3.0
|
—
|
|
EEG Spectrum Pre-Post tDCS Session
Theta_Post_Fp2
|
110.7 Power(10*log10(muV))^2
Standard Deviation 0.2
|
—
|
|
EEG Spectrum Pre-Post tDCS Session
Alpha_Post_Fp2
|
108.9 Power(10*log10(muV))^2
Standard Deviation 1.5
|
—
|
|
EEG Spectrum Pre-Post tDCS Session
Beta_Post_Fp2
|
105.9 Power(10*log10(muV))^2
Standard Deviation 0.4
|
—
|
|
EEG Spectrum Pre-Post tDCS Session
Gamma_Post_Fp2
|
105.2 Power(10*log10(muV))^2
Standard Deviation 0.1
|
—
|
SECONDARY outcome
Timeframe: Pre-treatment (baseline), throughout treatment (once a week for 7 weeks), 1 week and 1 month follow-ups (post-treatment)1-7 scale grading self-evaluated overall physical condition, 7= Excellent, 1 = Very poor.
Outcome measures
| Measure |
Transcranial Direct Current Stimulation (tDCS)
n=7 Participants
tDCS is a method of non-invasive brain stimulation that is based on the application of a weak direct current to the head that flows between two relatively large electrodes-anode and cathode. tDCS offers a unique analgesic modality of central pain neuromodulation by altering the activity of key sensory and motor cortical structures. Participants in this arm will undergo 20 tDCS sessions, tDCS in clinic and remotely supervised tDCS, and 2mA of transcranial direct current stimulation will be applied for 20 minutes.
Transcranial Direct Current Stimulation (tDCS): tDCS is a non-invasive brain neuromodulatory method that involves sending a weak electrical current to the brain. 2mA of tDCS will be applied for 20 minutes at each session and participants will undergo a total of 20 sessions over a 7-week period.
|
Chemoradiotherapy Standard of Care
n=1 Participants
The control group will consist of patients receiving the Standard of care and no neuromodulation.
|
|---|---|---|
|
Oral-Mucositis Weekly Evaluation - Overall
Pre-Study
|
4.9 score on a scale
Standard Deviation 1.1
|
7 score on a scale
|
|
Oral-Mucositis Weekly Evaluation - Overall
Week1
|
5 score on a scale
Standard Deviation 1
|
7 score on a scale
|
|
Oral-Mucositis Weekly Evaluation - Overall
Week2
|
4.8 score on a scale
Standard Deviation 1.5
|
7 score on a scale
|
|
Oral-Mucositis Weekly Evaluation - Overall
Week3
|
4.6 score on a scale
Standard Deviation 1.2
|
7 score on a scale
|
|
Oral-Mucositis Weekly Evaluation - Overall
Week4
|
4.9 score on a scale
Standard Deviation 0.6
|
7 score on a scale
|
|
Oral-Mucositis Weekly Evaluation - Overall
Week5
|
4.7 score on a scale
Standard Deviation 0.7
|
7 score on a scale
|
|
Oral-Mucositis Weekly Evaluation - Overall
Week6
|
4.7 score on a scale
Standard Deviation 0.7
|
7 score on a scale
|
|
Oral-Mucositis Weekly Evaluation - Overall
Week7
|
4.9 score on a scale
Standard Deviation 0.8
|
7 score on a scale
|
|
Oral-Mucositis Weekly Evaluation - Overall
FollowUp-Week1
|
4.5 score on a scale
Standard Deviation 1
|
7 score on a scale
|
|
Oral-Mucositis Weekly Evaluation - Overall
FollowUp-Month1
|
4.6 score on a scale
Standard Deviation 0.9
|
7 score on a scale
|
SECONDARY outcome
Timeframe: Pre-treatment (baseline), throughout treatment (once a week for 7 weeks), 1 week and 1 month follow-ups (post-treatment)Participant's weight each measurement time point. Note: 0 means data missing.
Outcome measures
| Measure |
Transcranial Direct Current Stimulation (tDCS)
n=7 Participants
tDCS is a method of non-invasive brain stimulation that is based on the application of a weak direct current to the head that flows between two relatively large electrodes-anode and cathode. tDCS offers a unique analgesic modality of central pain neuromodulation by altering the activity of key sensory and motor cortical structures. Participants in this arm will undergo 20 tDCS sessions, tDCS in clinic and remotely supervised tDCS, and 2mA of transcranial direct current stimulation will be applied for 20 minutes.
Transcranial Direct Current Stimulation (tDCS): tDCS is a non-invasive brain neuromodulatory method that involves sending a weak electrical current to the brain. 2mA of tDCS will be applied for 20 minutes at each session and participants will undergo a total of 20 sessions over a 7-week period.
|
Chemoradiotherapy Standard of Care
n=1 Participants
The control group will consist of patients receiving the Standard of care and no neuromodulation.
|
|---|---|---|
|
Patient Weight
Week5
|
218.7 pound
Standard Deviation 38.4
|
133 pound
|
|
Patient Weight
Pre-Study
|
229.2 pound
Standard Deviation 40.6
|
136.5 pound
|
|
Patient Weight
Week1
|
224.2 pound
Standard Deviation 42.0
|
140 pound
|
|
Patient Weight
Week2
|
246.2 pound
Standard Deviation 33.2
|
139.3 pound
|
|
Patient Weight
Week3
|
221.9 pound
Standard Deviation 38.5
|
137.5 pound
|
|
Patient Weight
Week4
|
222.8 pound
Standard Deviation 41.6
|
140.6 pound
|
|
Patient Weight
Week6
|
210.7 pound
Standard Deviation 37.8
|
132.8 pound
|
|
Patient Weight
Week7
|
212.6 pound
Standard Deviation 37.6
|
131.9 pound
|
|
Patient Weight
FollowUp-Week1
|
220.8 pound
Standard Deviation 27.5
|
132 pound
|
|
Patient Weight
FollowUp-Month1
|
206.2 pound
Standard Deviation 35.5
|
127.9 pound
|
SECONDARY outcome
Timeframe: Pre-treatment (baseline), throughout treatment (once a week for 7 weeks), 1 week and 1 month follow-ups (post-treatment)The General Positive and General Negative scores in the PANAS forms are reported for both pre- and post- treatment. The General Positive (GP) and General Negative (GN) scores were reported. Each score ranges from 10-50, in which 10 = lowest (positive/negative emotional level) and 50 = highest (positive/negative emotional level).
Outcome measures
| Measure |
Transcranial Direct Current Stimulation (tDCS)
n=7 Participants
tDCS is a method of non-invasive brain stimulation that is based on the application of a weak direct current to the head that flows between two relatively large electrodes-anode and cathode. tDCS offers a unique analgesic modality of central pain neuromodulation by altering the activity of key sensory and motor cortical structures. Participants in this arm will undergo 20 tDCS sessions, tDCS in clinic and remotely supervised tDCS, and 2mA of transcranial direct current stimulation will be applied for 20 minutes.
Transcranial Direct Current Stimulation (tDCS): tDCS is a non-invasive brain neuromodulatory method that involves sending a weak electrical current to the brain. 2mA of tDCS will be applied for 20 minutes at each session and participants will undergo a total of 20 sessions over a 7-week period.
|
Chemoradiotherapy Standard of Care
n=1 Participants
The control group will consist of patients receiving the Standard of care and no neuromodulation.
|
|---|---|---|
|
Positive and Negative Affect Schedule
GP-PRE-PreStudy
|
NA score on a scale
Standard Deviation NA
Data were not collected at the time point.
|
NA score on a scale
Data were not collected at the time point.
|
|
Positive and Negative Affect Schedule
GP-PRE-Week1
|
19 score on a scale
Standard Deviation 16
|
37 score on a scale
|
|
Positive and Negative Affect Schedule
GP-PRE-Week2
|
16 score on a scale
Standard Deviation 19
|
39 score on a scale
|
|
Positive and Negative Affect Schedule
GP-PRE-Week3
|
11 score on a scale
Standard Deviation 19
|
38 score on a scale
|
|
Positive and Negative Affect Schedule
GP-PRE-Week4
|
18 score on a scale
Standard Deviation 16
|
39 score on a scale
|
|
Positive and Negative Affect Schedule
GP-PRE-Week5
|
18 score on a scale
Standard Deviation 16
|
30 score on a scale
|
|
Positive and Negative Affect Schedule
GP-PRE-Week6
|
23 score on a scale
Standard Deviation 13
|
34 score on a scale
|
|
Positive and Negative Affect Schedule
GP-PRE-Week7
|
10 score on a scale
Standard Deviation 17
|
37 score on a scale
|
|
Positive and Negative Affect Schedule
GP-PRE-FollowupWeek1
|
21 score on a scale
Standard Deviation 15
|
35 score on a scale
|
|
Positive and Negative Affect Schedule
GP-PRE-FollowupMonth1
|
30 score on a scale
Standard Deviation 10
|
38 score on a scale
|
|
Positive and Negative Affect Schedule
GN-PRE-PreStudy
|
NA score on a scale
Standard Deviation NA
Data were not collected at the time point.
|
NA score on a scale
Data were not collected at the time point.
|
|
Positive and Negative Affect Schedule
GN-PRE-Week1
|
9 score on a scale
Standard Deviation 8
|
13 score on a scale
|
|
Positive and Negative Affect Schedule
GN-PRE-Week2
|
7 score on a scale
Standard Deviation 9
|
10 score on a scale
|
|
Positive and Negative Affect Schedule
GN-PRE-Week3
|
4 score on a scale
Standard Deviation 8
|
10 score on a scale
|
|
Positive and Negative Affect Schedule
GN-PRE-Week4
|
10 score on a scale
Standard Deviation 6
|
10 score on a scale
|
|
Positive and Negative Affect Schedule
GN-PRE-Week5
|
9 score on a scale
Standard Deviation 6
|
10 score on a scale
|
|
Positive and Negative Affect Schedule
GN-PRE-Week6
|
11 score on a scale
Standard Deviation 5
|
10 score on a scale
|
|
Positive and Negative Affect Schedule
GN-PRE-Week7
|
5 score on a scale
Standard Deviation 9
|
10 score on a scale
|
|
Positive and Negative Affect Schedule
GN-PRE-FollowupWeek1
|
10 score on a scale
Standard Deviation 7
|
10 score on a scale
|
|
Positive and Negative Affect Schedule
GN-PRE-FollowupMonth1
|
14 score on a scale
Standard Deviation 5
|
10 score on a scale
|
|
Positive and Negative Affect Schedule
GP-POST-PreStudy
|
NA score on a scale
Standard Deviation NA
Data were not collected at the time point.
|
NA score on a scale
Data were not collected at the time point.
|
|
Positive and Negative Affect Schedule
GP-POST-Week1
|
NA score on a scale
Standard Deviation NA
Data were not collected at the time point.
|
NA score on a scale
Data were not collected at the time point.
|
|
Positive and Negative Affect Schedule
GP-POST-Week2
|
14 score on a scale
Standard Deviation 12
|
NA score on a scale
Data were not collected at the time point.
|
|
Positive and Negative Affect Schedule
GP-POST-Week3
|
14 score on a scale
Standard Deviation 14
|
NA score on a scale
Data were not collected at the time point.
|
|
Positive and Negative Affect Schedule
GP-POST-Week4
|
14 score on a scale
Standard Deviation 10
|
NA score on a scale
Data were not collected at the time point.
|
|
Positive and Negative Affect Schedule
GP-POST-Week5
|
14 score on a scale
Standard Deviation 10
|
NA score on a scale
Data were not collected at the time point.
|
|
Positive and Negative Affect Schedule
GP-POST-Week6
|
NA score on a scale
Standard Deviation NA
Data were not collected at the time point.
|
NA score on a scale
Data were not collected at the time point.
|
|
Positive and Negative Affect Schedule
GP-POST-Week7
|
NA score on a scale
Standard Deviation NA
Data were not collected at the time point.
|
NA score on a scale
Data were not collected at the time point.
|
|
Positive and Negative Affect Schedule
GP-POST-FollowupWeek1
|
NA score on a scale
Standard Deviation NA
Data were not collected at the time point.
|
NA score on a scale
Data were not collected at the time point.
|
|
Positive and Negative Affect Schedule
GP-POST-FollowupMonth1
|
NA score on a scale
Standard Deviation NA
Data were not collected at the time point.
|
NA score on a scale
Data were not collected at the time point.
|
|
Positive and Negative Affect Schedule
GN-POST-PreStudy
|
NA score on a scale
Standard Deviation NA
Data were not collected at the time point.
|
NA score on a scale
Data were not collected at the time point.
|
|
Positive and Negative Affect Schedule
GN-POST-Week1
|
NA score on a scale
Standard Deviation NA
Data were not collected at the time point.
|
NA score on a scale
Data were not collected at the time point.
|
|
Positive and Negative Affect Schedule
GN-POST-Week2
|
13 score on a scale
Standard Deviation 12
|
NA score on a scale
Data were not collected at the time point.
|
|
Positive and Negative Affect Schedule
GN-POST-Week3
|
14 score on a scale
Standard Deviation 10
|
NA score on a scale
Data were not collected at the time point.
|
|
Positive and Negative Affect Schedule
GN-POST-Week4
|
13 score on a scale
Standard Deviation 10
|
NA score on a scale
Data were not collected at the time point.
|
|
Positive and Negative Affect Schedule
GN-POST-Week5
|
14 score on a scale
Standard Deviation 10
|
NA score on a scale
Data were not collected at the time point.
|
|
Positive and Negative Affect Schedule
GN-POST-Week6
|
NA score on a scale
Standard Deviation NA
Data were not collected at the time point.
|
NA score on a scale
Data were not collected at the time point.
|
|
Positive and Negative Affect Schedule
GN-POST-Week7
|
NA score on a scale
Standard Deviation NA
Data were not collected at the time point.
|
NA score on a scale
Data were not collected at the time point.
|
|
Positive and Negative Affect Schedule
GN-POST-FollowupWeek1
|
NA score on a scale
Standard Deviation NA
Data were not collected at the time point.
|
NA score on a scale
Data were not collected at the time point.
|
|
Positive and Negative Affect Schedule
GN-POST-FollowupMonth1
|
NA score on a scale
Standard Deviation NA
Data were not collected at the time point.
|
NA score on a scale
Data were not collected at the time point.
|
SECONDARY outcome
Timeframe: Pre-treatment (baseline), Week 7 of treatment, 1 week and 1 month follow-ups (post-treatment)The Washington Quality Of Life questionnaire (QOL) is one of the most frequently reported health-related QOL questionnaires in head and neck cancer. This questionnaire scaled from 0 (worst) to 100 (best) according to the hierarchy of response.
Outcome measures
| Measure |
Transcranial Direct Current Stimulation (tDCS)
n=7 Participants
tDCS is a method of non-invasive brain stimulation that is based on the application of a weak direct current to the head that flows between two relatively large electrodes-anode and cathode. tDCS offers a unique analgesic modality of central pain neuromodulation by altering the activity of key sensory and motor cortical structures. Participants in this arm will undergo 20 tDCS sessions, tDCS in clinic and remotely supervised tDCS, and 2mA of transcranial direct current stimulation will be applied for 20 minutes.
Transcranial Direct Current Stimulation (tDCS): tDCS is a non-invasive brain neuromodulatory method that involves sending a weak electrical current to the brain. 2mA of tDCS will be applied for 20 minutes at each session and participants will undergo a total of 20 sessions over a 7-week period.
|
Chemoradiotherapy Standard of Care
n=1 Participants
The control group will consist of patients receiving the Standard of care and no neuromodulation.
|
|---|---|---|
|
Washington Quality Of Life Questionnaire
Pre-Study
|
18.6 score on a scale
Standard Deviation 8.3
|
20 score on a scale
|
|
Washington Quality Of Life Questionnaire
Week7
|
34.3 score on a scale
Standard Deviation 4.9
|
10 score on a scale
|
|
Washington Quality Of Life Questionnaire
FollowUp-Week1
|
31.7 score on a scale
Standard Deviation 6.9
|
10 score on a scale
|
|
Washington Quality Of Life Questionnaire
FollowUp-Month1
|
28.6 score on a scale
Standard Deviation 3.5
|
10 score on a scale
|
SECONDARY outcome
Timeframe: Pre-treatment (baseline), throughout treatment (once a week for 7 weeks), 1 week and 1 month follow-ups (post-treatment)The Present Pain Intensity (PPI) index is recorded as a number ranges from 0 to 5, in which each number is associated with the following words: 0 no pain, 1 mild, 2 discomforting, 3 distressing, 4 horrible, 5 excruciating.
Outcome measures
| Measure |
Transcranial Direct Current Stimulation (tDCS)
n=7 Participants
tDCS is a method of non-invasive brain stimulation that is based on the application of a weak direct current to the head that flows between two relatively large electrodes-anode and cathode. tDCS offers a unique analgesic modality of central pain neuromodulation by altering the activity of key sensory and motor cortical structures. Participants in this arm will undergo 20 tDCS sessions, tDCS in clinic and remotely supervised tDCS, and 2mA of transcranial direct current stimulation will be applied for 20 minutes.
Transcranial Direct Current Stimulation (tDCS): tDCS is a non-invasive brain neuromodulatory method that involves sending a weak electrical current to the brain. 2mA of tDCS will be applied for 20 minutes at each session and participants will undergo a total of 20 sessions over a 7-week period.
|
Chemoradiotherapy Standard of Care
n=1 Participants
The control group will consist of patients receiving the Standard of care and no neuromodulation.
|
|---|---|---|
|
Present Pain Intensity Index in McGill Questionnaire Pre-tDCS Treatment
PPI PRE Week5
|
1.8 score on a scale
Standard Deviation 1.5
|
0 score on a scale
|
|
Present Pain Intensity Index in McGill Questionnaire Pre-tDCS Treatment
PPI PRE Week6
|
1.8 score on a scale
Standard Deviation 0.7
|
0 score on a scale
|
|
Present Pain Intensity Index in McGill Questionnaire Pre-tDCS Treatment
PPI PRE Week7
|
1.8 score on a scale
Standard Deviation 0.9
|
0 score on a scale
|
|
Present Pain Intensity Index in McGill Questionnaire Pre-tDCS Treatment
PPI PRE FollowUp Week1
|
1.2 score on a scale
Standard Deviation 0.9
|
0 score on a scale
|
|
Present Pain Intensity Index in McGill Questionnaire Pre-tDCS Treatment
PPI PRE FollowUp Month1
|
1.7 score on a scale
Standard Deviation 0.7
|
0 score on a scale
|
|
Present Pain Intensity Index in McGill Questionnaire Pre-tDCS Treatment
PPI PRE Pre-Study
|
0.9 score on a scale
Standard Deviation 1.1
|
0 score on a scale
|
|
Present Pain Intensity Index in McGill Questionnaire Pre-tDCS Treatment
PPI PRE Week1
|
0.4 score on a scale
Standard Deviation 1.0
|
0 score on a scale
|
|
Present Pain Intensity Index in McGill Questionnaire Pre-tDCS Treatment
PPI PRE Week2
|
0.7 score on a scale
Standard Deviation 1.0
|
0 score on a scale
|
|
Present Pain Intensity Index in McGill Questionnaire Pre-tDCS Treatment
PPI PRE Week3
|
1.7 score on a scale
Standard Deviation 1.0
|
0 score on a scale
|
|
Present Pain Intensity Index in McGill Questionnaire Pre-tDCS Treatment
PPI PRE Week4
|
2.0 score on a scale
Standard Deviation 1.4
|
0 score on a scale
|
Adverse Events
Transcranial Direct Current Stimulation (tDCS)
Serious events: 0 serious events
Other events: 0 other events
Deaths: 0 deaths
Chemoradiotherapy Standard of Care
Serious events: 0 serious events
Other events: 0 other events
Deaths: 0 deaths
Serious adverse events
Adverse event data not reported
Other adverse events
Adverse event data not reported
Additional Information
Alexandre DaSilva
University of Michigan, School of Dentistry
Phone: 7346153807
Email: [email protected]
Results disclosure agreements
- Principal investigator is a sponsor employee
- Publication restrictions are in place